GlaxoSmithKline Biologicals SA (GSK) filed a legal action against multiple companies under the Moderna umbrella, concerning patent EP2590626 B1. The court issued a procedural order addressing two main applications. Firstly, GSK's request to have experts heard in person (under R. 176) was dismissed because they failed to specify the facts the experts would confirm, and such detailed hearings don't align with UPC's framework. Secondly, Moderna's request for an extension to file a rejoinder (under R. 9.3) was denied due to lack of exceptional circumstances, despite the complexity of the issues. This is in line with UPC's goal of timely resolving cases. The court also invited parties to suggest additional topics for an upcoming Interim Conference.